We also explored common metabolic mechanisms between neurodegenerative diseases such as DE and AD, and developed therapeutic strategies for metabolic reprogramming such as GLP-1 receptor agonists, NAD+ boosters, and AMPK activators. The gene discussed is GLP1R; the disease is Alzheimer disease.